1
Country: USA | Funding: $316.6M
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts utilizing T2MR target sepsis, hemostasis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts utilizing T2MR target sepsis, hemostasis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.
2
Country: USA | Funding: $228.6M
CytoVale is a medical technology company that focuses on advancing early detection technologies to diagnose immune-mediated diseases.
CytoVale is a medical technology company that focuses on advancing early detection technologies to diagnose immune-mediated diseases.
3
Country: USA | Funding: $73.6M
Potrero Medical is a predictive health company focused on using smart sensors and analytics for early detection of critical illnesses. Its patient monitoring platform that detects sepsis and fluid overload in ICU patients via urinary catheter
Potrero Medical is a predictive health company focused on using smart sensors and analytics for early detection of critical illnesses. Its patient monitoring platform that detects sepsis and fluid overload in ICU patients via urinary catheter
4
Country: USA | Funding: $67M
Immunexpress, a molecular diagnostics company, developed a product pipeline to address the unmet clinical needs of sepsis patients, as well as the professional needs of clinicians, payers, and healthcare systems.
Immunexpress, a molecular diagnostics company, developed a product pipeline to address the unmet clinical needs of sepsis patients, as well as the professional needs of clinicians, payers, and healthcare systems.
5
Country: South Korea | Funding: $37.6M
Ilias Biologics is developing various therapeutic exosomes, a potential treatment for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory and metabolic areas.
Ilias Biologics is developing various therapeutic exosomes, a potential treatment for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory and metabolic areas.
